Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) (NCT03476070) | Clinical Trial Compass
UnknownNot Applicable
Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)
Singapore236 participantsStarted 2018-06-18
Plain-language summary
This study aims to evaluate the prevalence, biological mechanism and survivorship impact of cognitive toxicity among adolescent and young adult (AYA) patients diagnosed with curable cancers. The hypothesis is that cognitive impairment is clinically significant among AYA cancer patients treated with chemotherapy and that there will be detectable structural and functional changes in the brain for this patient group.
Who can participate
Age range
15 Years – 39 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* between 15-39 years of age
* newly diagnosed with breast cancer, lymphoma or germ cell tumor with treatment intent determined as curative by medical oncologist
* scheduled for chemotherapy with or without non-cranial radiotherapy
* no prior history of chemotherapy and/or radiotherapy
* able to read and understand English
* capable of giving informed consent (or obtaining parents' consent if required)
Exclusion Criteria:
* physically or mentally incapable of providing verbal/written consent
* diagnosed with primary or metastatic brain tumor(s) or relapsed disease
* treatment includes intrathecal or intraventricular chemotherapy
* evidence of psychosis or underlying neuropsychiatric illness that may impair cognitive abilities
* have immediate family member who is enrolled as in the healthy control arm
* any contraindication to MRI as stated in the study protocol including: pregnancy, metal fragments/implants in body, known claustrophobia, and non-removable metal orthodontic braces, metallic retainers and oral wires
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prevalence of cognitive impairment in AYA cancer patients